Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

Abstract

PD-1 inhibitors in combination with chemo have shown efficacy in G/GEJ cancer. We present results of the double-blind, placebo-controlled KEYNOTE-859 study of pembro + fluoropyrimidine- and platinum-containing chemo for advanced HER2-negative G/GEJ cancer (NCT03675737).

PD-1 inhibitors in combination with chemo have shown efficacy in G/GEJ cancer. We present results of the double-blind, placebo-controlled KEYNOTE-859 study of pembro + fluoropyrimidine- and platinum-containing chemo for advanced HER2-negative G/GEJ cancer (NCT03675737).